Future Directions

1. The Disease-Modifying Problem

Sixty-eight years after Carlsson, all approved PD therapies are symptomatic: they replace dopamine, modulate downstream circuits, or suppress complications, but none alters the underlying neurodegeneration. The disease-modifying therapy (DMT) gap is the central scientific and clinical problem of modern PD.

The graveyard of failed neuroprotection trials is long: vitamin E (DATATOP), CoQ10 (QE3), creatine (NET-PD LS-1), pioglitazone, isradipine (STEADY-PD III), inosine (SURE-PD3), GDNF (multiple, beginning in 2003). Each was based on plausible biology; each failed an unselected disease-stage cohort using motor endpoints. The lessons drawn:

• Stratify by biology — LRRK2 carriers, GBA carriers, RBD-prodromal, SAA-positive subgroups all carry distinct biology, prognosis, and target rationale.
• Treat earlier — manifest motor PD already has >50% nigral neuron loss; prodromal or even pre-clinical stages may be the only realistic window.
• Use biomarker endpoints — DaTscan progression, SAA kinetics, plasma synuclein, neurofilament light chain (NfL) — with motor endpoints as confirmatory.
• Embrace target engagement — many trials failed to confirm that the drug actually engaged its target in brain at the dose tested.

2. Anti-α-Synuclein Antibodies

The PD analogue of anti-amyloid immunotherapy in AD: passive immunisation with monoclonal antibodies aimed at extracellular α-synuclein, intended to neutralise propagating seeds and reduce prion-like spread.

• Prasinezumab (Roche/Prothena) — targets aggregated α-synuclein. The PASADENA trial (Pagano et al., NEJM 2022) missed its primary motor endpoint at 52 weeks but showed signals on MDS-UPDRS-III subgroups. PADOVA Phase IIb (2024) failed primary, but again with subgroup signals in patients on background MAO-B-i and faster progressors. Programme is being re-evaluated.
• Cinpanemab (BIIB054, Biogen) — targeted N-terminal α-synuclein. SPARK Phase II halted 2021 for futility — no signal of motor or biomarker benefit.
• Lu AF82422 (Lundbeck/Genmab) — in Phase II for MSA (AMULET); Phase I PD.
• UCB7853 / minzasolmin (UCB) — small-molecule synuclein aggregation inhibitor; Phase II ORCHESTRA trial in early PD.
• Active vaccines — AFFITOPE PD01A/PD03A (now Vincerx) — small synuclein-mimotope peptides; early-phase positive immunogenicity.

The early antibody failures echo aducanumab’s difficult path in AD. The field has learned that target engagement (CSF synuclein reduction), biomarker evidence of pathology slowing, and patient stratification (GBA carriers, early/prodromal stages) are necessary — not sufficient — conditions for success.

3. α-Synuclein Lowering Approaches

Given that SNCA gene-dosage alone causes PD, lowering α-synuclein expression is an obvious therapeutic axis:

• Antisense oligonucleotides (ASOs) — intrathecal anti-SNCA ASOs (Biogen/Ionis ION464) in early development, parallel to ASO programmes in HD and ALS.
• RNAi — AAV-delivered synuclein siRNA in preclinical models; gene therapy hurdles around delivery and durability.
• Small-molecule SNCA expression modulators — e.g., posiphen (Annovis Bio) modulates SNCA mRNA translation. Mixed Phase II results.
• Aggregation inhibitors — minzasolmin, anle138b (MODAG/Teva), small molecules that bind misfolded oligomers and fibrils.
• Augmenting clearance — chaperone-mediated autophagy and lysosomal-targeted strategies; nilotinib (a tyrosine-kinase inhibitor that increases autophagy) has failed multiple trials but principle continues.

4. GBA-Targeted Therapy

GBA carriers are an attractive target population: they have a defined molecular defect (reduced GCase activity), a clear mechanistic link to synuclein (Mazzulli, Cell 2011), and a recognisable clinical phenotype (faster progression, more dementia). Three therapeutic strategies:

• Pharmacological chaperones — ambroxol, the over-the-counter mucolytic, binds and stabilises GCase, increasing its activity. Mullin et al. (JAMA Neurol 2020) showed that high-dose ambroxol crosses the BBB, raises brain GCase activity, and is well tolerated in GBA-PD patients. The ASPro-PD trial (UK; complete; results imminent) and AiM-PD will determine whether this translates to clinical benefit.
• Substrate reduction therapy (SRT) — venglustat (Sanofi GZ/SAR402671) is a glucosylceramide synthase inhibitor that reduces the GCase substrate when the enzyme is failing. The MOVES-PD Phase II in GBA-PD failed primary motor endpoint (2021). Mechanism remains plausible; trial design under reconsideration.
• AAV-GBA gene therapy — PR001/LY3884961 (Prevail Therapeutics, now Lilly), intra-cisternal AAV delivery of GBA1, in Phase I/II for both GBA-PD and Type 2/3 Gaucher disease. Early data show GCase enzyme activity restoration in CSF.

5. LRRK2 Inhibitors

Pathogenic LRRK2 mutations (G2019S and others) all act by kinase gain-of-function; therefore brain-penetrant LRRK2 kinase inhibitors should reduce disease activity. After early hurdles (peripheral lung/kidney pathology in some preclinical compounds), several selective inhibitors have entered the clinic:

• BIIB122 / DNL151 (Biogen/Denali) — the lead programme; Phase IIa LIGHTHOUSE in LRRK2-PD and Phase IIb LUMA in idiopathic PD running 2022–2026.
• DNL201 (Denali, predecessor) — demonstrated robust pRab10/pSer935 reduction in Phase I; superseded by DNL151.
• MK-1468 (Merck) — in development.

An open question: do LRRK2 inhibitors benefit only LRRK2 carriers, or also idiopathic PD, where LRRK2 kinase activity may be elevated downstream of synuclein pathology (Di Maio, Hastings et al., Sci Transl Med 2018)? The LUMA trial addresses exactly this.

6. Gene Therapy — AAV Approaches

Adeno-associated virus (AAV) vectors carrying therapeutic transgenes have been tested in PD for two decades, with three main strategies:

• AAV-AADC — intra-putaminal delivery of aromatic L-amino-acid decarboxylase, enabling restoration of L-DOPA-to-dopamine conversion in a denervated putamen. NBIb-1817 (Voyager/Neurocrine; PD-1101 RESTORE) showed modest improvement in motor function. Newer programme: AB-1005 (AskBio/Bayer) GAD-AADC with MRI-guided delivery.
• AAV-GDNF / AAV-neurturin — aimed at neurotrophic support of dying SNc neurons. CERE-120 (Ceregene; AAV2-neurturin) failed a Phase II trial in 2008 and a Phase IIb in 2013, partly due to ineffective putaminal delivery; AAV-GDNF programmes (Brain Neurotherapy Bio) continue with improved convection-enhanced delivery.
• AAV-GBA1 (Prevail/Lilly PR001) — for GBA-PD, restoring lysosomal GCase activity (above).
• AAV-GAD (NLX-P101, Neurologix) — STN delivery of GAD to convert excitatory STN to inhibitory; Phase II positive but commercial development stalled.

Common challenges: durable transgene expression, immune response, MRI-guided precision delivery to small targets (putamen, SNc), and ensuring blanket coverage of the diseased volume. CRISPR-based approaches (e.g., to silence SNCA in carriers) remain in preclinical development.

7. Stem-Cell Transplantation

Cell-replacement therapy — transplanting dopamine-producing neurons into the denervated striatum — has the longest experimental history in PD, dating to fetal mesencephalic transplants in the 1980s. The early open-label Lund/Halifax trials showed motor benefit in some patients, but the double-blind NIH-funded Freed (NEJM 2001) and Olanow (Ann Neurol 2003) trials produced mixed results with troubling graft-induced dyskinesias, halting the field. The Kordower-Olanow-Brundin observation (Nat Med 2008) that 14-year-old grafts develop Lewy bodies further complicated the picture by demonstrating prion-like host-to-graft spread.

The modern era uses human pluripotent stem cell (hPSC) derived dopamine neuron precursors, which are scalable, GMP-grade, and characterised. Several Phase I/II programmes are running:

• Kyoto University trial (Takahashi lab) — iPSC-derived dopamine progenitors. Transplantation began 2018; first results published 2024 showing safety and biological evidence of dopamine cell engraftment.
• BlueRock Therapeutics (Bayer) — bemdaneprocel (BRT-DA01); Phase I exPLORE-PD published 2024 showed safety and motor improvement signals; Phase II/III initiated.
• STEM-PD (Lund/Skåne) — European hESC-derived dopamine cells; Phase I in progress.
• Aspen Neuroscience (autologous iPSC) — personalised iPSC-derived autologous transplants; Phase I.

Key open questions: durable graft survival, optimal cell fraction (purity), avoidance of dyskinesias, immune-rejection management (autologous vs allogeneic with HLA matching), and crucially — in a disease with prion-like spread — whether grafts will themselves succumb to host pathology over a decade.

8. Exercise, Diet, and the Microbiome

The non-pharmacological evidence base for PD is increasingly robust:

• Exercise — high-intensity aerobic exercise (treadmill at ~80% HRmax) slows motor decline in early PD (SPARX trial, Schenkman et al., JAMA Neurol 2018; Park-in-Shape, van der Kolk et al., Lancet Neurol 2019). Mechanisms include BDNF upregulation, dopaminergic plasticity, and direct effects on striatal LTP. Resistance training, tai chi, dance (LSVT-BIG, Ramazzini, tango), and rhythmic auditory stimulation all have evidence.
• Mediterranean / MIND diet — observationally associated with reduced PD risk and slower progression. Mechanisms include reduced systemic inflammation and improved gut microbiome composition.
• Caffeine — ~30% reduction in PD risk in meta-analyses; istradefylline (A2A antagonist; FDA-approved 2019 as L-DOPA adjunct in Japan) builds on this signal.
• Smoking — the most reproducible negative association in epidemiology; nicotine neuroprotection trials (NIC-PD with transdermal patches) have so far been negative or inconclusive.
• Vitamin D, urate (the SURE-PD3 inosine trial was negative despite epidemiological signals), CoQ10, creatine, vitamin E — all individually negative or inconsistent in DMT trials.
• Microbiome — the gut-microbiome axis (see Part III) has produced active interventional trials: faecal microbiota transplantation (Kuai, Brain 2023; pilot positive); probiotic and prebiotic studies; targeted bacterial modulation.

The take-home: exercise is the single intervention with the strongest evidence for slowing PD progression, recommended at every stage and now an integral part of MDS guidelines.

9. Atypical Parkinsonism — Their Own Pipelines

The Parkinson-plus syndromes (PSP, MSA, CBD, DLB) have distinct molecular biology and are now drawing dedicated therapeutic effort:

• PSP (4R-tauopathy) — anti-tau monoclonals tilavonemab (NEJM 2021, negative), gosuranemab (NEJM 2021, negative); ASOs against MAPT (BIIB080); microtubule stabilisers (TPI-287, davunetide; both negative).
• MSA (oligodendroglial synucleinopathy) — MSA-specific anti-α-synuclein antibodies (Lu AF82422 AMULET); ATH-1027 / fosgonimeton (oligodendrocyte-targeted); rapamycin (autophagy enhancement).
• CBD/CBS — same anti-tau pipeline as PSP; few CBS-specific trials due to phenotypic heterogeneity.
• DLB — cholinesterase inhibitors (donepezil, rivastigmine, MIND-AD); pimavanserin for psychosis; same anti-synuclein pipeline as PD.

Several lessons cut across: stratification by underlying biology (4R-tau vs synuclein vs mixed pathology) is essential, and basket-trial designs that include multiple syndromes with shared mechanism are an emerging structural innovation.

10. The Outlook for the 2030s

The next decade in PD will probably look like this:

1. Biological diagnosis becomes routine — SAA in CSF or skin redefines PD as a synuclein disease, not a clinical syndrome, and allows pre-motor identification of prodromal carriers.
2. Stratified DMT trials — LRRK2 carriers, GBA carriers, RBD-prodromal cohorts, SAA-positive pre-clinical groups become the trial populations of choice. Drug-target matching replaces “all comers” designs.
3. First successful DMT readouts — an LRRK2 inhibitor (BIIB122) and/or an anti-synuclein antibody and/or an ambroxol-class GBA chaperone is plausible to read out positive on biomarker endpoints by 2027–2028; clinical efficacy a few years later.
4. Cell therapy matures — bemdaneprocel and Kyoto trial outcomes will determine whether stem-cell transplantation finds a clinical niche (probably for advanced motor disease, complementary to DBS).
5. Adaptive DBS & MRgFUS expand — β-band closed-loop DBS becomes standard; FUS-mediated BBB opening enables targeted drug delivery to specific brain regions.
6. Prevention — for high-risk groups (LRRK2, GBA carriers, RBD), the next step after DMT validation is primary prevention before motor onset. The “PD A4” equivalent is on the horizon.
7. Health-system burden grows — the Parkinson pandemic continues; even with DMT, prevalence will roughly double by 2050. Health-economic preparation, especially in middle-income countries, is as important as molecular therapy.

For deeper foundations on the molecular biology, see Part III (α-Synuclein); for genetics, see Part IV; for diagnostic biomarkers, see Part VI; and for the symptomatic-therapy landscape that DMTs will need to integrate into, Part VII. Cross-courses: Alzheimer’s Disease, Neuroscience, Cell Physiology, Pharmacology, and Stroke.

Two centuries after James Parkinson’s 1817 essay, his “shaking palsy” has at last become tractable as biology. The translation from biology to bedside — bending the trajectory of an individual patient’s disease — is the work of the coming decade.